Life Technologies Corporation
) diagnostic testing menu is set to gain from the recent U.S.
Food and Drug Administration's (FDA) 510(k) clearance for two
infectious disease tests of the company's partner
). According to both the companies, FDA recently allowed Quidel's
Molecular Influenza A+B assay and Molecular RSV + hMPV assay to
run on QuantStudio Dx Real-Time PCR Instrument, Life
Technologies' flagship instrument for the diagnostics market.
Quidel's Influenza A+B assay determines whether patients have
the influenza A and/or B virus and detect the H7N9 subtype.
According to the company, this subtype shows 30% mortality rate
in China. Human exposure to infected poultry is the prime cause
of transmission of H7N9 infections in human. However, recently
the British Medical Journalreleased a probable case of
human-to-human transmission of this infection.
On the other hand, Quidel's RSV + hMPV assay diagnoses two
lung infections, respiratory syncytial virus (RSV) and human
metapneumovirus (hMPV). hMPV accounts for 7.1% of respiratory
tract infections. Thus, Life Technologies believes these
clearances will help the company to expand its infectious disease
detection menu, available on the QuantStudio Dx instrument.
Of late, Life Technologies has sharpened its focus on product
platforms with a string of new product launches over the recent
past. The disclosure of its impending acquisition by
Thermo Fisher Scientific Inc.
) will further boost LIFE's product suite. With the overwhelming
approval of its stockholders in favor of the deal, the impending
acquisition of Life Technologies is now subject to customary
We are also encouraged by Life Technologies' strategy to
strengthen its presence in high-growth geographic markets such as
Latin America, the Middle-East, China, and India. Life
Technologies views immense potential in applied markets where
technologies can help to carry out biological research in
fast-growing industries such as forensics, and food and water
Over the next few years, Life Technologies' focus on
developing industry-leading franchises in high-growth technology
areas, applied markets and emerging geographies will be the key
driver for long-term growth.
Currently, the LIFE stock carries a Zacks Rank #3 (Hold). On
the other hand,
), carrying a Zacks Rank #2 (Buy) is worth considering.
EXACTECH INC (EXAC): Free Stock Analysis
LIFE TECHNOLOGS (LIFE): Free Stock Analysis
QUIDEL CORP (QDEL): Free Stock Analysis
THERMO FISHER (TMO): Free Stock Analysis
To read this article on Zacks.com click here.